News

Nexavar® approved in the U.S. to treat liver cancer

Leverkusen – The cancer drug Nevaxar® has become the first product to receive marketing authorization in the United States for the treatment of liver cancer. The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for info

Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. In Europe, Nexavar® was approved for the treatment of HCC in October 2007. It is the only drug therapy shown to significantly improve overall survival in patients with the disease.

In late 2005, after a development time of only ten years, Nexavar® was introduced to the market as the first new treatment for advanced kidney cancer. It is now approved for this indication in more than 60 countries. The product is being jointly developed by Bayer HealthCare AG and Onyx Pharmaceuticals, Inc.